PARIS (Reuters) – Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, said it had launched a two gene test to detect the presence of the COVID-19 virus.
Novacyt added that France’s Haute Autorit de Sant, which advises the government on medical reimbursement, had told the company that the two gene COVID-19 test would qualify for reimbursement for use by French testing laboratories.
(Reporting by Sudip Kar-Gupta; editing by Jason Neely)
